Questcor Pharmaceuticals (QCOR) is a classic example of stock that moves independently of its company. Its performance in the market is largely dictated by mere speculation instead of its financial position. Despite the company's strong financial profile, its current share price is substantially below 52-week highs. The company suffered a major blow when Citron made a press release on Questcor's flagship product, Acthar Gel. The press release broke the news about AETNA's decision to delist Acthar Gel from its list of reimbursable drugs for all indications except infantile spasms.
The news came in the wake of increasing sales and robust growth. However, panicked investors paid little attention to the present financial standings of the company, but traded based on the negative impact of the news. It has been six months now, since the news was released and there are still no signs of weakening sales. Instead, the year-end reports showed that the company became much stronger than before.
Immediately after the major plunge last September 2012, the stock prices gradually bounced back and partially recovered as investors' confidence was lifted by encouraging financial results. However, the question remains whether the stock can fully recover to its peak level or not. This is a question that must be addressed before buying QCOR stocks. Let's look at the company's financial profile.
Can you read and comprehend? Do you know what an external appeal process is? Are you familiar with the requirement of pre-authorization? Do you know what information manipulation consists of? This you must know because you are one big perpetrator of this action. Stop masquerading around as a clear headed honesty providing purveyor of information...this you are not. Just a dishonest, subtle provider of misinformation...in other words a danged dishonest shorty. We know you for what you are. Innocence is not your true mantra.
Sentiment: Strong Buy
Master, EPS shall clear all "confusion", I believe in EPS and FCF as the ultimate "confusion clearers". Investors think long term. Shorts think, what else, short term. I do think confusion may take a while longer to clear, therefore shorts enjoy your time in the sun, and beware of some PE firm enamored by QCOR's FCFs and pristine B/S coming in and bringing ultimate nightfall to all shorts.
LuvDat, I like that.
But what about the other indications, why does AETNA not cover it. according to Mikey AETNA does cover case by case basis
there is so much confusion
in absence of clear conviction , shorts thrive and win.
If everything is clear as black and white , shorts have no chance, but since so much confusion is around it , that is the main reason for pressure on PPS. SMART Money ( dumb money ) is managed by ignorant uneducated ppl. country is run by criminals and thugs. i don't need further explanation
so unless util longs clear everything nothing is going to happen.
Aetna considers repository corticotropin (H.P. Acthar® Gel) medically necessary for West syndrome (infantile spasms)
Aetna considers repository corticotropin not medically necessary for diagnostic testing of adrenocortical function because it has not been shown to be superior to cosyntropin for this purpose.
Aetna considers repository corticotropin not medically necessary for corticosteroid-responsive conditions because it has not been proven to be more effective than corticosteroids for these indications.
Aetna considers repository corticotropin experimental and investigational for all other indications because its effectiveness for these indications has not been established.
Citron scary... NOT
Articles people write long or short.... usually just opinion and uneducated at that
MasterShortSeller.... still afraid to send me an email and compare notes.
Strange Longs are resorting to foul language when the article they themselves posted SAYS:
he company suffered a major blow when Citron made a press release on Questcor's flagship product, Acthar Gel. The press release broke the news about AETNA's decision to delist Acthar Gel from its list of reimbursable drugs for all indications except infantile spasms.
END OF QUOTE
THe question was simple: AETNA's decision to delist Acthar Gel from its list of reimbursable drugs for all indications except infantile spasms ?
Why ACTH got delisted except for IS ?
please no need for shallow speech. we are all mature enough